CRISPR Stock Future Price Prediction

CRSP
 Stock
  

USD 66.15  0.75  1.12%   

CRISPR Therapeutics stock price prediction is an act of determining the future value of CRISPR Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of CRISPR Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of CRISPR Therapeutics and does not consider all of the tangible or intangible factors available from CRISPR Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with CRISPR Therapeutics AG, which may create opportunities for some arbitrage if properly timed.
Continue to CRISPR Therapeutics Basic Forecasting Models to cross-verify your projections.
  
Refresh
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of CRISPR Therapeutics based on different types of headlines from major news networks to social media. The CRISPR stock price prediction module provides an analysis of price elasticity to changes in media outlook on CRISPR Therapeutics over a specific investment horizon.Using CRISPR Therapeutics hype-based prediction, you can estimate the value of CRISPR Therapeutics AG from the perspective of CRISPR Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
CRISPR Therapeutics Enterprise Value over EBIT is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Enterprise Value over EBIT of 13.00. As of 28th of June 2022, Enterprise Value over EBITDA is likely to grow to 13.50, while Current Ratio is likely to drop 19.30.
This module is based on analyzing investor sentiment around taking a position in CRISPR Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in CRISPR Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying CRISPR because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

CRISPR Therapeutics after-hype prediction price

    
  $ 66.9  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of CRISPR Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of CRISPR Therapeutics in the context of predictive analytics.
Intrinsic
Valuation
LowReal ValueHigh
60.2191.8191.81
Details
16 Analysts
Consensus
LowTarget PriceHigh
100.00160.69220.00
Details
Earnings
Estimates (10)
LowProjected EPSHigh
4.765.005.29
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as CRISPR Therapeutics. Your research has to be compared to or analyzed against CRISPR Therapeutics' peers to derive any actionable benefits. When done correctly, CRISPR Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in CRISPR Therapeutics.

CRISPR Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of CRISPR Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in CRISPR Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many smart people who confused the symmetrical distributions of stock prices, such as prices of CRISPR Therapeutics, with the unreliable approximations that try to describe financial returns.
 Next price density 
      Expected price to next headline 

CRISPR Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting CRISPR Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on CRISPR Therapeutics' historical news coverage. CRISPR Therapeutics' after-hype downside and upside margins for the prediction period are 66.90 and 66.90, respectively. We have considered CRISPR Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value 66.15
66.90
After-hype Price
66.90
Upside
CRISPR Therapeutics is very steady asset. Analysis and calculation of next after-hype price of CRISPR Therapeutics is based on 3 months time horizon.

CRISPR Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a company such as CRISPR Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CRISPR Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with CRISPR Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.22  5.53   0.39   0.00  8 Events / Month1 Events / MonthIn about 8 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
66.1566.900.00 
314.20  

CRISPR Therapeutics Hype Timeline

CRISPR Therapeutics is currently traded for 66.15. The entity has historical hype elasticity of -0.39 and average elasticity to hype of competition of 0.0. CRISPR projected not to react to the next headlinewith price going to stay at about the same level and average media hype impact volatility of over 100%. The immediate return on the next newsis projected to be very small whereas the daily expected return is currently at 0.22%. The volatility of relative hype elasticity to CRISPR Therapeutics is about 0.0%. The volatility of related hype on CRISPR Therapeutics is about 0.0% with expected price after next announcement by competition of 66.15. About 61.0% of the company shares are held by institutions such as insurance companies. The book value of CRISPR Therapeutics was currently reported as 29.01. The company has Price/Earnings To Growth (PEG) ratio of 0.04. CRISPR Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next projectedpress releasewill be in about 8 days.
Continue to CRISPR Therapeutics Basic Forecasting Models to cross-verify your projections.

CRISPR Therapeutics Related Hype Analysis

Having access to credible news sources related to CRISPR Therapeutics' direct competition is more important than ever and may enhance your ability to predict CRISPR Therapeutics' future price movements. Getting to know how CRISPR Therapeutics rivals react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how CRISPR Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
PLSQFPlus500 0.00 4 per month 0.00  0.53  0.00  0.00  2.47 

CRISPR Therapeutics Additional Predictive Modules

Most predictive techniques to examine CRISPR price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for CRISPR using various technical indicators. When you analyze CRISPR charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About CRISPR Therapeutics Predictive Indicators

The successful prediction of CRISPR Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as CRISPR Therapeutics AG, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of CRISPR Therapeutics based on analysis of CRISPR Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to CRISPR Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to CRISPR Therapeutics's related companies.

Story Coverage note for CRISPR Therapeutics

The number of cover stories for CRISPR Therapeutics depends on current market conditions and CRISPR Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that CRISPR Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about CRISPR Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

CRISPR Therapeutics Short Properties

CRISPR Therapeutics' future price predictability will typically decrease when CRISPR Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of CRISPR Therapeutics AG often depends not only on the future outlook of the potential CRISPR Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CRISPR Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Shares Percent Shares Out13.21%
Short Percent Of Float15.30%
Float Shares76.32M
Average Daily Volume Last 10 Day3.73M
Shares Short Prior Month10.14M
Average Daily Volume In Three Month1.71M
Date Short Interest31st of May 2022
Continue to CRISPR Therapeutics Basic Forecasting Models to cross-verify your projections. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.